Pionyr Immunotherapeutics (formerly Precision Immune Inc.) is discovering and developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Pionyr has licensed technology from UC San Francisco and University of Toronto for the identification of novel immune-oncology targets, cellular assays, generation of monoclonal antibody therapeutics, and other targets and technologies.

Pionyr has also established a collaboration with Adimab, the leader in antibody discovery, optimization, and production for the option to license Adimab-generated antibodies to Pionyr’s proprietary targets.

For further information, please contact Pionyr’s VP of Business Operations at .

University of Toronto